Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Temozolomide + TRC102 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TRC102 | Methoxyamine|TRC-102 | TRC102 (Methoxyamine) inhibits the base excision repair pathway, potentially resulting in increased sensitivity to chemotherapeutic agents and anti-tumor activity (J Clin Oncol 34, 2016 (suppl; abstr 2556), PMID: 23054206, PMID: 32556884). | ||
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01851369 | Phase Ib/II | Temozolomide + TRC102 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | Completed | USA | 0 |